ALTB-268

Therapeutic Area Indication

Therapeutic Area

Product Overview
Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a multiple-valence molecule to achieve a better efficacy. From preliminary experimental results, ALTB-268 exhibits not only comparable preliminary safety profiles, but also improved potency in eliminating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equal efficacy in clinical is expected.

Indication

Ulcerative Colitis Solid Organ Transplantation

Ulcerative Colitis

1

  • PRECLINICAL

  • PHASE I

    Phase 1

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

Introduction

Based on the structure of ALTB-168. ALTB-268, a second generation of the therapeutic antibody with multivalent design that leads to improve potency, is being under development. In vitro and in vivo studies with ALTB-268 have demonstrated a potentially 10-fold increase in activity of abolishing activated T cells (immune cells that cause inflammation).
The company is dedicated to bringing forth ALTB-268, currently in Phase 1 trial with heathy volunteers, into multiple autoimmune indications. Ulcerative colitis will be the first indication to be explored based on solid proof of clinical efficacy achieved with ALTB-168.

Solid Organ Transplantation

2

  • PRECLINICAL

    Preclinical

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

Introduction

Solid organ transplantation is a potentially life-saving option for patients faced with terminal organ failure. However, immunosuppressive drugs are needed for prevention of rejection of transplanted organs and long-term administration of immunosuppressive medications has potential unfavorable consequences including increased susceptibility to opportunistic infections and malignancies.

Because of the unique MOA of ALTB-168, we believe it has the potential for a durable response allowing patients to avoid long-term administration of immunosuppressive medications. We are currently studying the use of ALTB-168 in preclinical non-human primate renal transplantation models.